Pyxis OncologyPYXS
Recorded

Pyxis Oncology 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration20 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael SchmidtAnalyst

Fireside Chat. My name is Michael Schmidt, and I am pleased to welcome the Pyxis team. With us today, we have Tom Civik, CEO. Tom, welcome. Thanks for joining us.

Thomas CivikCEO

Thank you for having us.

Michael SchmidtAnalyst

Pyxis is at an interesting junction here. Before we go into the details, maybe just talk about MICVO lead program, which targets the tumor stroma, a little different than what other ADCs are targeting, and why is it exciting, and why is head and neck cancer the right place to start?

Thomas CivikCEO

Yeah, it is such a great question, Michael, and really the reason I joined Pyxis was a completely novel first-in-concept ADC gives me a lot of excitement and to pursue something that has not been done before. We started off with this thesis that targeting the extracellular matrix with an ADC could have really profound impact on many different cancers. But a small biotech, we have to focus on where the signal is the strongest, and in a fairly large basket study, we saw a really strong signal in head and neck cancer, and we decided to follow that not only because of the strong signal, but because the unmet need was significant.

Thomas CivikCEO

The treatment options for patients in second line head and neck cancer are really not that great. We felt like there was an opportunity there with a clinical signal, the unmet need, and a pretty significant size population of patients that were desperate for something better. What I will say is what we've learned through our first phase I study was the initial hypothesis was that you needed a lot of what's called EDB-FN, or extradomain-B fibronectin, that you find in the extracellular matrix, and you don't find it anywhere outside the tumor cell, which is an interesting component to it.

Thomas CivikCEO

We had this thesis that you needed a lot of it to be able to find where our drug would be effective, and in the phase I study, we did in head and neck cancer, we did an EDB-FN H-score and found that actually all you need is a little bit of EDB-FN to find efficacy with our drug. That's exciting for a couple different reasons. One is that you probably don't need any sort of biomarker-driven therapy, but two, it opens up opportunities for significant life cycle options beyond head and neck cancer. The way the extracellular matrix works, and EDB-FN specifically, is we find this in almost every solid tumor today. While we're excited about the head and neck opportunity and the data that we shared just a couple months ago, I think the life cycle options are quite significant for this program.

Michael SchmidtAnalyst

Right. Before we dive into the head and neck data, what other tumor types are on your radar?

Thomas CivikCEO

Yeah, in our large basket study, we had nine tumors that showed activity, and they are the ones that you would expect, like breast cancer or lung cancer, pancreatic cancer, sarcoma. We use a pretty straightforward decision-making criteria to think about where we're going to invest our time and our resources, and it starts off with, where do you see activity in the clinic? It's followed by, where can we become standard of care in a patient population that's large enough to matter?

Thomas CivikCEO

We are going to use those same two criteria as we think about where we are going to go next, but I do not want to dilute my message, which is we have a really significant opportunity in second line head and neck, where the current treatment options are pretty poor, and a pivotal trial that we are already starting to set up to get this program to the market as quickly as possible.

Michael SchmidtAnalyst

The head and neck cancer landscape is changing. We have just seen top-line data for new EGFR-directed bispecific antibodies announced a couple of weeks ago. Amivantamab just received accelerated approval a few days ago in second line. Where does MICVO fit in, and how do you expect the market to evolve longer term?

Thomas CivikCEO

Well, I mean, first off, I can say personally, I am celebrating the advancements that are being done in head and neck cancer. This was an area that did not receive a lot of investment for many, many years, and we have three fairly large programs focused on the frontline setting as we speak, and you mentioned a few of them. I think to answer your question about where does this position MICVO today, it is clear that the standard of care is changing in the frontline setting, and we had consistently said that it was a matter of both if and when. I think it is probably a little bit more clear that it is now just a question of when EGFRs move into the frontline.

Thomas CivikCEO

What happens, like we see in other cancers, like endometrial cancer, small cell cancer, some different subgroups of lung cancer, is that when the frontline changes, it leaves the patients in second line and beyond with very few options. This is where MICVO is really uniquely positioned in our study, which I know we will talk a little bit more about later. We looked at patients following both the current standard of care in frontline, which is platinum plus PD-1s, but also those patients that get EGFR bispecifics or EGFR inhibitors plus PD-1s, and we saw really universal efficacy regardless of what their prior treatment was. This, I think, answers a really significantly large unmet need for patients in the second line and beyond. Today, what is nearest term for us is an opportunity to have a big impact for second line head and neck cancer.

Michael SchmidtAnalyst

You had a very important data update just recently in September from your ongoing phase I study. Just remind us what the key takeaways were from that.

Thomas CivikCEO

Yeah, thank you for that, and it is exciting to talk about the data that we disclosed a couple months ago, and I think there are two main takeaways from what we shared. One is, in a heavily pre-treated patient population, we saw three consecutive versions of efficacy. Really impressive response rate, 36% overall, regardless of HPV status or prior therapy. We saw over six months of progression-free survival, and we had a 79% 12-month OS probability. All three of those efficacy signals really important. Early response rate leading to survival benefit, PFS, and overall survival. Then, secondarily, we saw a really manageable safety profile. We had implemented modified weight-based dosing at the end of last year to really see if we could have a positive impact on things like discontinuation and grade 3 peripheral neuropathy. The implementation of that dose cap cut both of those nearly in half.

Thomas CivikCEO

One of the areas based upon our payload that we have been paying a lot of attention to is peripheral neuropathy. It is something that we have been working with the investigators across the globe on. I think what we saw in this data, Michael, was that peripheral neuropathy happens late. It often resolves, and patients receive a really significant benefit. This is a benefit-risk conversation for the physicians and patients that we think has been answered with the data that we shared in September.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day